Table 4– Association of treatment success with patient characteristics and multidrug-resistant tuberculosis (MDR-TB) patient group
CasesAdjusted odds of treatment success versus treatment failure/relapse/death#
Male (versus female)46531.0 (0.9–1.1)
Older age (per 10-year increment)67240.8 (0.8–0.9)
HIV infected (versus not HIV infected)6150.3 (0.2–0.4)
Extensive disease (versus not extensive)47920.5 (0.4–0.6)
Previous TB treatment
 None12751.0 (Reference)
 First-line drugs only44100.6 (0.5–0.8)
 First-line and second-line drugs6180.2 (0.15–0.3)
MDR-TB patient group+
 MDR-TB only47631.0 (Reference)
 MDR+INJr11300.6 (0.5–0.7)
 MDR+FQr4260.3 (0.2–0.4)
 XDR-TB4050.2 (0.2–0.3)
Pulmonary resection surgery performed (versus no pulmonary resection surgery)+3731.5 (0.9–2.6)
Experienced a serious adverse event (versus no serious adverse event)+15111.0 (0.8–1.2)
  • Data are presented as n or adjusted OR (95% CI). TB: tuberculosis; MDR-TB: multidrug-resistant TB (resistance to at least isoniazid and rifampicin); MDR-TB only: MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested); MDR-TB+INJr: MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones; MDR-TB+FQr: MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested); XDR-TB: extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)). #: odds ratios of treatment success (cure and completion) versus treatment failure/relapse/death adjusted for age, sex, HIV infection, previous TB treatment, previous MDR treatment (treatment for >1 month with two or more second-line drugs) and extent of disease. See Methods and [17] for treatment outcome definitions. : estimate adjusted for all other covariates (characteristics) shown. +: each of these parameters estimated separately, and adjusted for age, sex, HIV, extent of disease and previous treatment with first- or second-line TB drugs. Statistical significance is represented by bold type.